Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.51 |
| ▸ | LMNA | P02545 | 8/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1813107 | 1.00 | KMT2A (0.53) | KMT2AMEN1ALDH1A1LMNATDP1 | |
| SCHEMBL993621 | 0.86 | ALDH1A1 (0.68) | KMT2AMEN1ALDH1A1LMNATDP1 | |
| SCHEMBL7049102 | 0.85 | GAA (0.60) | KMT2AMEN1ALDH1A1LMNATDP1 | |
| SCHEMBL13419533 | 0.84 | ALDH1A1 (0.66) | KMT2AMEN1ALDH1A1LMNATDP1 | |
| SCHEMBL30278668 | 0.84 | ALDH1A1 (0.66) | KMT2AMEN1ALDH1A1LMNATDP1 | |
| SCHEMBL398803 | 0.84 | ALDH1A1 (0.61) | KMT2AMEN1ALDH1A1LMNAKDM4E | |
| SCHEMBL30410222 | 0.84 | ALDH1A1 (0.61) | KMT2AMEN1ALDH1A1LMNAKDM4E | |
| SCHEMBL15321459 | 0.82 | ALDH1A1 (0.71) | KMT2AMEN1ALDH1A1LMNATDP1 | |
| SCHEMBL16824862 | 0.82 | ALDH1A1 (0.66) | ALDH1A1LMNATDP1KDM4EMAPT | |
| SCHEMBL16824850 | 0.82 | ALDH1A1 (0.60) | KMT2AMEN1ALDH1A1LMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | KMT2A 3362/4885MEN1 1978/4885ALDH1A1 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.